BioXcel Therapeutics (BTAI)
Nasdaq Market Closed
BioXcel Therapeutics, Inc. is a biopharmaceutical company that develops medicines for neuroscience and immuno-oncology indications. The company is best known for applying artificial intelligence and data-driven drug development tools to identify new uses, formulations, and clinical paths for therapeutic candidates with established biological rationale. Its strategy is to use technology to shorten discovery work and focus resources on assets that can address high-need medical conditions.
The company’s lead commercial product is IGALMI, a sublingual film formulation of dexmedetomidine. The US Food and Drug Administration approves IGALMI for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The product is designed to dissolve under the tongue and provides a non-invasive option in settings where rapid calming is needed without an injection.
BioXcel’s pipeline includes BXCL501, the development name behind IGALMI, which the company studies in additional agitation-related and neuropsychiatric settings. It also develops BXCL701, an oral small-molecule candidate in immuno-oncology. BXCL701 is intended to stimulate immune activity in the tumor microenvironment and is investigated in cancer indications where new combinations or immune-based approaches may improve outcomes.
As a listed biotechnology stock, BTAI gives investors exposure to a company transitioning between clinical development and commercial execution. Its prospects depend on regulatory progress, clinical trial results, physician adoption, reimbursement, and the company’s ability to fund and advance its development programs.
Last updated
- Market Cap
- 36.74M
- P/E
- —
- P/FCF
- —
- P/S
- 54.04
- Enterprise Value
- 119.85M
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Address
- 555 LONG WHARF DRIVE, NEW HAVEN, CT, 06511
Levi & Korsinsky, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of BioXcel Therapeutics, Inc.
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering
BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation
BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements
UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®
BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025
BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia
Neuroendocrine Prostate Cancer Market Forecast Shows Accelerated CAGR Due to Diagnostic Advancements and Research Investment | DelveInsight
BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement
Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsight
BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
BioXcel Therapeutics Announces Proposed Public Offering
BioXcel Therapeutics Announces Preliminary Estimated - GlobeNewswire
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
BioXcel Therapeutics Announces $25 Million Registered Direct Offering
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
BioXcel Therapeutics Announces Termination of Proposed Public Offering
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 36.74M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 119.85M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- -0.35
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 54.04
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -2.39
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 176.25
- EPS
- -2.44
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- —
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 71.38%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -221.41%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- -0.95
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 0.62
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 0.61
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.31
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 704.18K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 1.19
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 206K | 256K | 98K | 120K | 168K |
| Gross profit | -77K | 224K | 87K | 13K | 154K |
| Operating income | -10.22M | -10.28M | -14.23M | -15.85M | -10.1M |
| EBITDA | -10.17M | -10.21M | -13.96M | -15.78M | -10.02M |
| Net income | -12.69M | -12.55M | -30.91M | -19.19M | -7.25M |
| Basic EPS | -0.54 | 0.65 | -2.18 | -2.45 | -1.5 |
| Diluted EPS | -0.54 | 0.65 | -2.18 | -2.45 | -1.5 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 34.03M | 44.92M | 44.79M | 25.79M | 38.57M |
| Total liabilities | 139.57M | 140.38M | 133.71M | 133.46M | 128.74M |
| Total equity | -105.54M | -95.46M | -88.92M | -107.67M | -90.17M |
| Cash & equivalents | 17.18M | 28.42M | 36.18M | 17.44M | 31.01M |
| Current assets | 33.91M | 44.34M | 43.26M | 24.1M | 37.78M |
| Current liabilities | 54.99M | 53.93M | 37.8M | 33.38M | 25.55M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -11.81M | -14.21M | -18.79M | -12.58M | -12.04M |
| Investing cash flow | — | — | — | — | — |
| Financing cash flow | 232K | 5.65M | 37.53M | 137K | 13.2M |
| Change in cash | -11.58M | -8.56M | 18.75M | -12.44M | 1.16M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 4 — BioXcel Therapeutics, Inc. | View Filing | |
| edgar index | 4 — BioXcel Therapeutics, Inc. | View Filing | |
| edgar index | 4 — BioXcel Therapeutics, Inc. | View Filing | |
| edgar index | 4 — BioXcel Therapeutics, Inc. | View Filing | |
| edgar index | 144 — BioXcel Therapeutics, Inc. | View Filing | |
| edgar index | 144 — BioXcel Therapeutics, Inc. | View Filing | |
| edgar index | 144 — BioXcel Therapeutics, Inc. | View Filing | |
| edgar index | 144 — BioXcel Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Mehta Vimal | View Filing | |
| form 4 | Form 4 — Steinhart Richard I | View Filing | |
| form 4 | Form 4 — Rodriguez Javier | View Filing | |
| form 4 | Form 4 — Yocca Frank | View Filing | |
| edgar index | 10-Q — BioXcel Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — BioXcel Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G — BioXcel Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — BioXcel Therapeutics, Inc. | View Filing | |
| edgar index | 4 — BioXcel Therapeutics, Inc. | View Filing | |
| edgar index | 4 — BioXcel Therapeutics, Inc. | View Filing | |
| edgar index | 4 — BioXcel Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Mehta Vimal | View Filing | |
| form 4 | Form 4 — Mehta Vimal | View Filing | |
| form 4 | Form 4 — Mehta Vimal | View Filing | |
| form 4 | Form 4 — Mehta Vimal | View Filing | |
| form 4 | Form 4 — Steinhart Richard I | View Filing | |
| form 4 | Form 4 — Steinhart Richard I | View Filing | |
| form 4 | Form 4 — Rodriguez Javier | View Filing | |
| form 4 | Form 4 — Rodriguez Javier | View Filing | |
| form 4 | Form 4 — Yocca Frank | View Filing | |
| form 4 | Form 4 — Yocca Frank | View Filing | |
| form 4 | Form 4 — Rodriguez Javier | View Filing | |
| form 4 | Form 4 — Rodriguez Javier | View Filing | |
| form 4 | Form 4 — Yocca Frank | View Filing | |
| form 4 | Form 4 — Yocca Frank | View Filing | |
| form 4 | Form 4 — Steinhart Richard I | View Filing | |
| form 4 | Form 4 — Steinhart Richard I | View Filing | |
| form 4 | Form 4 — Mehta Vimal | View Filing | |
| form 4 | Form 4 — Mehta Vimal | View Filing | |
| form 4 | Form 4 — Mehta Vimal | View Filing | |
| form 4 | Form 4 — Mehta Vimal | View Filing | |
| edgar index | 8-K — BioXcel Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — BioXcel Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — BioXcel Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — BioXcel Therapeutics, Inc. | View Filing | |
| edgar index | 10-K — BioXcel Therapeutics, Inc. | View Filing | |
| edgar index | S-8 — BioXcel Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 4 — BioXcel Therapeutics, Inc. | View Filing | |
| edgar index | 4 — BioXcel Therapeutics, Inc. | View Filing | |
| edgar index | 4 — BioXcel Therapeutics, Inc. | View Filing | |
| edgar index | 4 — BioXcel Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Yocca Frank | View Filing | |
| form 4 | Form 4 — Yocca Frank | View Filing | |
| form 4 | Form 4 — Rodriguez Javier | View Filing | |
| form 4 | Form 4 — Rodriguez Javier | View Filing | |
| form 4 | Form 4 — Steinhart Richard I | View Filing | |
| form 4 | Form 4 — Steinhart Richard I | View Filing | |
| form 4 | Form 4 — Mehta Vimal | View Filing | |
| form 4 | Form 4 — Mehta Vimal | View Filing | |
| form 4 | Form 4 — Yocca Frank | View Filing | |
| form 4 | Form 4 — Yocca Frank | View Filing | |
| form 4 | Form 4 — Rodriguez Javier | View Filing | |
| form 4 | Form 4 — Rodriguez Javier | View Filing | |
| form 4 | Form 4 — Steinhart Richard I | View Filing | |
| form 4 | Form 4 — Steinhart Richard I | View Filing | |
| form 4 | Form 4 — Mehta Vimal | View Filing | |
| form 4 | Form 4 — Mehta Vimal | View Filing | |
| form 4 | Form 4 — Mehta Vimal | View Filing | |
| form 4 | Form 4 — Mehta Vimal | View Filing | |
| edgar index | 424B5 — BioXcel Therapeutics, Inc. | View Filing |